Literature DB >> 22511760

Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.

Huihui Chong1, Xue Yao, Zonglin Qiu, Bo Qin, Ruiyun Han, Sandro Waltersperger, Meitian Wang, Sheng Cui, Yuxian He.   

Abstract

The core structure of HIV-1 gp41 is a stable six-helix bundle (6-HB) folded by its trimeric N- and C-terminal heptad repeats (NHR and CHR). We previously identified that the (621)QIWNNMT(627) motif located at the upstream region of gp41 CHR plays critical roles for the stabilization of the 6-HB core and peptide CP621-652 containing this motif is a potent HIV-1 fusion inhibitor, however, the molecular determinants underlying the stability and anti-HIV activity remained elusive. In this study, we determined the high-resolution crystal structure of CP621-652 complexed by T21. We find that the (621)QIWNNMT(627) motif does not maintain the α-helical conformation. Instead, residues Met(626) and Thr(627) form a unique hook-like structure (denoted as M-T hook), in which Thr(627) redirects the peptide chain to position Met(626) above the left side of the hydrophobic pocket on the NHR trimer. The side chain of Met(626) caps the hydrophobic pocket, stabilizing the interaction between the pocket and the pocket-binding domain. Our mutagenesis studies demonstrate that mutations of the M-T hook residues could completely abolish HIV-1 Env-mediated cell fusion and virus entry, and significantly destabilize the interaction of NHR and CHR peptides and reduce the anti-HIV activity of CP621-652. Our results identify an unusual structural feature that stabilizes the six-helix bundle, providing novel insights into the mechanisms of HIV-1 fusion and inhibition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22511760      PMCID: PMC3370210          DOI: 10.1074/jbc.M112.354126

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41.

Authors:  Y Weng; Z Yang; C D Weiss
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 2.  Molecular strategies to design an escape-proof antiviral therapy.

Authors:  Ben Berkhout; Rogier W Sanders
Journal:  Antiviral Res       Date:  2011-04-12       Impact factor: 5.970

3.  Buried polar interactions and conformational stability in the simian immunodeficiency virus (SIV) gp41 core.

Authors:  H Ji; C Bracken; M Lu
Journal:  Biochemistry       Date:  2000-02-01       Impact factor: 3.162

Review 4.  Inhibition of HIV-1 by fusion inhibitors.

Authors:  Dirk Eggink; Ben Berkhout; Rogier W Sanders
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 5.  Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor.

Authors:  Avraham Ashkenazi; Yael Wexler-Cohen; Yechiel Shai
Journal:  Biochim Biophys Acta       Date:  2011-07-05

6.  Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides.

Authors:  W Shu; J Liu; H Ji; L Radigen; S Jiang; M Lu
Journal:  Biochemistry       Date:  2000-02-22       Impact factor: 3.162

7.  Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.

Authors:  Xue Yao; Huihui Chong; Chao Zhang; Sandro Waltersperger; Meitian Wang; Sheng Cui; Yuxian He
Journal:  J Biol Chem       Date:  2012-01-06       Impact factor: 5.157

8.  Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease.

Authors:  Stephanie Bertram; Ilona Glowacka; Marcel A Müller; Hayley Lavender; Kerstin Gnirss; Inga Nehlmeier; Daniela Niemeyer; Yuxian He; Graham Simmons; Christian Drosten; Elizabeth J Soilleux; Olaf Jahn; Imke Steffen; Stefan Pöhlmann
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

9.  Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis.

Authors:  M Lu; M O Stoller; S Wang; J Liu; M B Fagan; J H Nunberg
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions.

Authors:  Victor Buzon; Ganesh Natrajan; David Schibli; Felix Campelo; Michael M Kozlov; Winfried Weissenhorn
Journal:  PLoS Pathog       Date:  2010-05-06       Impact factor: 6.823

View more
  22 in total

1.  Structural basis of potent and broad HIV-1 fusion inhibitor CP32M.

Authors:  Xue Yao; Huihui Chong; Chao Zhang; Zonglin Qiu; Bo Qin; Ruiyun Han; Sandro Waltersperger; Meitian Wang; Yuxian He; Sheng Cui
Journal:  J Biol Chem       Date:  2012-06-07       Impact factor: 5.157

2.  Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.

Authors:  Yang Su; Huihiui Chong; Shengwen Xiong; Yuanyuan Qiao; Zonglin Qiu; Yuxian He
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

3.  Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.

Authors:  Yang Su; Huihiui Chong; Zonglin Qiu; Shengwen Xiong; Yuxian He
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

4.  A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Xiaoran Tang; Hongliang Jin; Yue Chen; Li Li; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

5.  The M-T hook structure is critical for design of HIV-1 fusion inhibitors.

Authors:  Huihui Chong; Xue Yao; Jianping Sun; Zonglin Qiu; Meng Zhang; Sandro Waltersperger; Meitian Wang; Sheng Cui; Yuxian He
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

6.  A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Shengwen Xiong; Pedro Borrego; Xiaohui Ding; Yuanmei Zhu; Andreia Martins; Huihui Chong; Nuno Taveira; Yuxian He
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

7.  The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.

Authors:  Yuanmei Zhu; Xiaohui Ding; Danwei Yu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

8.  Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.

Authors:  Danwei Yu; Xiaohui Ding; Zixuan Liu; Xiyuan Wu; Yuanmei Zhu; Huanmian Wei; Huihui Chong; Sheng Cui; Yuxian He
Journal:  J Biol Chem       Date:  2018-06-21       Impact factor: 5.157

9.  Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.

Authors:  Xiaohui Ding; Xiujuan Zhang; Huihui Chong; Yuanmei Zhu; Huamian Wei; Xiyuan Wu; Jinsheng He; Xinquan Wang; Yuxian He
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

10.  Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Huihui Chong; Yuanmei Zhu; Danwei Yu; Yuxian He
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.